Skip to main content
Erschienen in: Netherlands Heart Journal 1/2024

Open Access 01.01.2024 | Editorial

Welcome to the new editor-in-chief

verfasst von: Jan J. Piek

Erschienen in: Netherlands Heart Journal | Ausgabe 1/2024

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Seven years ago, I took over the position of editor-in-chief of the Netherlands Heart Journal from Professor Ernst van der Wall, who had served the journal for 30 years. When I started I expected to act as editor-in-chief for just a few years. However, it takes time to form a new editorial board and further build on Professor van der Wall’s good work.
The Netherlands Heart Journal is among the few journals of national cardiac societies with an impact factor. Our journal is a platform for open discussions on new developments within our profession. We welcome opinion papers to endorse discussion between our members on interpretation of novel diagnostic and therapeutic findings, and also on the application of international guidelines at the national level. The quality of submissions, and in particular the frequently cited and downloaded review articles, has led to an improvement in our impact factor. One of the highlights of the journal was the special issue on cardiac research in the Netherlands, on the occasion of the ESC Congress 2020 in Amsterdam. Unfortunately, this special issue could not be distributed in person, as the ESC meeting was virtual during the COVID pandemic.
During the last year, there was a gradual transition of an old towards a new editorial board and a good timing to step down as editor-in-chief. I am very pleased to welcome Professor Pim van der Harst as the new editor-in-chief. Professor van der Harst is an interventional cardiologist, scientist and head of the Department of Cardiology of the University Medical Center Utrecht. With his background, I am confident that he will lead the new editorial board in a dedicated fashion towards the future. With his team he will contribute to improve the quality of our journal by bringing science and content of our national society together.
I would like to thank the previous deputy editors, Professors Jolanda van der Velden, Ron Peters, Yigal Pinto and Rob de Winter for their dedicated work and Lieda Meester and Lucienne Bongers for their supportive role. Moreover, I wish Professor Pim van der Harst and his team, Dr. Maryam Kavousi, Dr. Peter Damman, Professor Joris de Groot and Dr. Martin Hemels all the best for their esteemed work in the new editorial board.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Welcome to the new editor-in-chief
verfasst von
Jan J. Piek
Publikationsdatum
01.01.2024
Verlag
Bohn Stafleu van Loghum
Erschienen in
Netherlands Heart Journal / Ausgabe 1/2024
Print ISSN: 1568-5888
Elektronische ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-023-01848-2

Weitere Artikel der Ausgabe 1/2024

Netherlands Heart Journal 1/2024 Zur Ausgabe

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.